JP2024517431A5 - - Google Patents
Info
- Publication number
- JP2024517431A5 JP2024517431A5 JP2023565206A JP2023565206A JP2024517431A5 JP 2024517431 A5 JP2024517431 A5 JP 2024517431A5 JP 2023565206 A JP2023565206 A JP 2023565206A JP 2023565206 A JP2023565206 A JP 2023565206A JP 2024517431 A5 JP2024517431 A5 JP 2024517431A5
- Authority
- JP
- Japan
- Prior art keywords
- ray powder
- powder diffraction
- solid
- exhibiting
- solid form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178752P | 2021-04-23 | 2021-04-23 | |
| US63/178,752 | 2021-04-23 | ||
| PCT/US2022/025815 WO2022226221A1 (en) | 2021-04-23 | 2022-04-21 | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024517431A JP2024517431A (ja) | 2024-04-22 |
| JP2024517431A5 true JP2024517431A5 (cg-RX-API-DMAC7.html) | 2025-05-02 |
| JP7825636B2 JP7825636B2 (ja) | 2026-03-06 |
Family
ID=83723159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565206A Active JP7825636B2 (ja) | 2021-04-23 | 2022-04-21 | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12692248B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326255A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7825636B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240000540A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117529313A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022261159A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023021916A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216258A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307910A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012521A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI922665B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022226221A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020371727B2 (en) | 2019-10-24 | 2026-01-22 | Pierre Fabre Medicament | Inhibitors of RAF kinases |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| TW202308645A (zh) | 2021-04-23 | 2023-03-01 | 美商奇奈特生物製藥公司 | 使用raf抑制劑之癌症治療 |
| JP7825636B2 (ja) | 2021-04-23 | 2026-03-06 | ピエール ファーブル メディカモン | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| EP2252612B1 (en) | 2008-02-22 | 2012-03-28 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Rafキナーゼ阻害剤として有用なヘテロアリール化合物 |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| KR101652229B1 (ko) | 2012-06-07 | 2016-08-30 | 데시페라 파마슈티칼스, 엘엘씨. | 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| JP6636014B2 (ja) | 2014-09-12 | 2020-01-29 | ノバルティス アーゲー | Rafキナーゼ阻害剤としての化合物および組成物 |
| CA3107014A1 (en) | 2018-07-31 | 2020-02-06 | AusCann Group Holdings Ltd | Solid self-emulsifying pharmaceutical compositions |
| WO2020168172A1 (en) | 2019-02-15 | 2020-08-20 | Zamboni Chem Solutions Inc. | Conjugate compounds for the degradation of raf |
| JP2022525885A (ja) * | 2019-03-22 | 2022-05-20 | キネート バイオファーマ インク. | Rafキナーゼの阻害剤 |
| CN114072148A (zh) | 2019-05-03 | 2022-02-18 | 金耐特生物制药公司 | Raf激酶的抑制剂 |
| AU2020371727B2 (en) | 2019-10-24 | 2026-01-22 | Pierre Fabre Medicament | Inhibitors of RAF kinases |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| JP7825636B2 (ja) | 2021-04-23 | 2026-03-06 | ピエール ファーブル メディカモン | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 |
| TW202308645A (zh) | 2021-04-23 | 2023-03-01 | 美商奇奈特生物製藥公司 | 使用raf抑制劑之癌症治療 |
-
2022
- 2022-04-21 JP JP2023565206A patent/JP7825636B2/ja active Active
- 2022-04-21 WO PCT/US2022/025815 patent/WO2022226221A1/en not_active Ceased
- 2022-04-21 IL IL307910A patent/IL307910A/en unknown
- 2022-04-21 US US18/556,243 patent/US12692248B2/en active Active
- 2022-04-21 MX MX2023012521A patent/MX2023012521A/es unknown
- 2022-04-21 AU AU2022261159A patent/AU2022261159A1/en active Pending
- 2022-04-21 CA CA3216258A patent/CA3216258A1/en active Pending
- 2022-04-21 CN CN202280044060.6A patent/CN117529313A/zh active Pending
- 2022-04-21 EP EP22792520.3A patent/EP4326255A4/en active Pending
- 2022-04-21 KR KR1020237039724A patent/KR20240000540A/ko active Pending
- 2022-04-21 BR BR112023021916A patent/BR112023021916A2/pt unknown
- 2022-04-22 TW TW111115523A patent/TWI922665B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU652046B2 (en) | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present | |
| JP4931874B2 (ja) | リモナバントの結晶多形の製造方法 | |
| US20090092669A1 (en) | Stable imatinib compositions | |
| US10189860B2 (en) | Hydrates of dolutegravir sodium | |
| JP2018168180A (ja) | バルサルタンおよびahu−377を含む三ナトリウム塩超分子複合体の新規な結晶形及びその製造方法 | |
| US20100010098A1 (en) | Polymorphs of rasagiline hydrochloride | |
| WO1996036595A1 (en) | 3,4-disubstituted-phenylsulphonamides and their therapeutic use | |
| EP1286670A2 (en) | Use of therapeutic benzamide derivatives | |
| JP7825636B2 (ja) | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 | |
| JP2022532404A5 (cg-RX-API-DMAC7.html) | ||
| KR20100126238A (ko) | N,n-디메틸 이미도디카르본이미딕 디아미드의 디카르복실산염, 그의 제조 방법 및 그의 약제학적 조성물 | |
| JP2023548160A (ja) | 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸の結晶性粒子の製造方法およびそれを含む薬学的組成物 | |
| JP2000500732A (ja) | 2−(4−置換)−ベンジルアミノ−2−メチル−プロパンアミド誘導体 | |
| CA2483597A1 (en) | New pharmaceutical compositions containing flibanserin polymorph a | |
| CN116869915A (zh) | 含有苯并咪唑衍生物的新型制剂 | |
| JP2007509143A5 (cg-RX-API-DMAC7.html) | ||
| PL183867B1 (pl) | Nowe indazolokarboksyamidy, sposób ich wytwarzania i środek farmaceutyczny | |
| AU2017254950B2 (en) | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein | |
| JP4278652B2 (ja) | 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物 | |
| JP2021529805A5 (cg-RX-API-DMAC7.html) | ||
| TW200900392A (en) | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same | |
| JP2024542840A5 (cg-RX-API-DMAC7.html) | ||
| HUP0402553A2 (hu) | Venlafaxin-hidroklorid-monohidrát, eljárások előállítására, az ezt tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| JP7226697B2 (ja) | ブロナンセリン含有錠剤 | |
| JP7628020B2 (ja) | アキシチニブを有効成分とする医薬錠剤 |